Date: 2015-02-19
Type of information: Initiation of patient enrollment
phase: 1
Announcement: initiation of patient enrollment
Company: Novavax (USA - MD)
Product: Ebola GP Vaccine (Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™)
Action mechanism:
Disease: Ebola fever
Therapeutic area: Infectious diseases
Country: Australia
Trial
details: The Ebola GP Vaccine clinical trial, which is being conducted in Australia, is a randomized, observer-blinded, dose-ranging Phase 1 study to evaluate the safety and immunogenicity of the vaccine, with and without Matrix-M adjuvant, in 230 healthy adult subjects between 18 and 50 years of age. Each subject will receive two intramuscular injections, one each on study days 0 and 21. In addition to the trial\'s primary goal of evaluating safety in this population, the study will also evaluate immunogenicity as measured by concentrations of serum IgG antibodies to the Ebola Makona strain glycoprotein. Secondary study endpoints include epitope-specific immune responses to the Ebola GP antigen as measured by serum titers in a competitive ELISA assay using known-neutralizing monoclonal antibodies, as well as serum Ebola virus neutralizing antibody reciprocal titers.
Latest
news: * On February 12, 2015, Novavax, a clinical-stage vaccine company focused on recombinant nanoparticle vaccines and adjuvants, announced that enrollment has begun in a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™ (Ebola GP Vaccine) in healthy subjects. Novavax initiated the development of its Ebola GP Vaccine shortly after the publication of the genetic sequence of the 2014 Ebola Makona strain (previously referred to as the 2014 Ebola Guinea strain), which is responsible for the current Ebola epidemic in West Africa. In an expedited time-frame, from the publication of the Makona sequence in September 2014, Novavax has developed the vaccine, scaled-up GMP manufacturing, delivered positive results from multiple relevant animal models, including a non-human primate challenge study, and initiated a Phase 1 clinical trial. The Phase 1 clinical trial initiation is supported by significant immunogenicity and efficacy data demonstrating that the Ebola GP Vaccine is the first subunit Ebola GP-based vaccine to provide protection in non-human primates. Non-human primates received two injections of a 5ug dose of the Ebola GP Vaccine with the Matrix-M adjuvant, and were challenged with a lethal dose of Ebola virus. As expected, the challenge was lethal for the control animal whereas, in sharp contrast, 100% of the immunized animals were protected. Additionally, the Ebola GP Vaccine induced Ebola Makona strain GP antibody titers of 106 (ELISA EC90) after two doses and 104, after a single dose, both results well above the range reported to provide protection in non-human primate models and reported in recent Ebola Phase 1 clinical trials. The rapid progression to a Phase I clinical trial is further supported by Novavax\' GMP manufacturing process, as documented in the February 10, 2015 online publication of BioProcessing Journal. The article titled \"Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology\" details Novavax\' manufacturing development process from genetic engineering of the 2014 Makona strain gene sequence through master seed preparation, qualification of analytical methods, and ultimately GMP manufacture with product release three months after project initiation.
